In pre-JPM interview, Viehbacher says rare disease, immunology, and neurology are of interestSAN FRANCISCO — Biogen would like to make additional biotech acquisitions in 2025 beyond Friday’s offer to buy its financially troubled partner Sage Therapeutics, chief executive Chris Viehbacher told me Sunday.“We will be doing deals — the size of those deals, I cannot […]
